Net loss: ($18.8M) (-25.3%); loss/share: ($0.45) (-18.4%); Quick Assets: $65.4M (+20.9%).
Topline data for Phase 3 trial of DEXTENZA for ocular itching associated with allergic conjunctivitis anticipated in H1 2020.
Previously: Ocular Therapeutix EPS beats by $0.01, misses on revenue (Nov. 12)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.